Previous 10 | Next 10 |
Novocure (NASDAQ: NVCR) today announced organizational changes to prepare for future growth, effective Jan. 17. Pritesh Shah, Novocure’s Chief Commercial Officer, will transition into a new executive role as Chief Growth Officer. In this role, Mr. Shah will have worldwide responsibilit...
Novocure (NASDAQ: NVCR) announced good news earlier this month from a late-stage study evaluating its Tumor-Treating Fields (TTFields) therapy in treating non-small cell lung cancer (NSCLC). Its shares skyrocketed. But just a few days later, the company provided a sneak peek at its ...
H.C. Wainwright reaffirmed the Buy rating on oncology-focused medical equipment maker NovoCure Limited ( NASDAQ: NVCR ) on Thursday despite a loss of ~16% of its value early this week after pre-announcing lower-than-expected Q4 financials. The maker of the Optune brand of cancer treat...
Novocure ( NASDAQ: NVCR ) is down ~15% in Monday afternoon trading after releasing preliminary Q4 2022 figures that came in below estimates. The oncology focused pharma is expecting Q4 net revenue of $128.4 million, below the consensus in $128.69M. As of December 31, 2022, the...
Summary Powered by the robust Phase 3 (LUNAR) trial, NovoCure Limited shares recently rallied over 70% in one trading session. You can expect Tumor Treating Field to be approved for non-small cell lung cancer sometime next year. Later this year, two huge Phase 3 studies are set to r...
Preliminary full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival Novocure announces first patients t...
Shares of NovoCure (NASDAQ: NVCR) , a maker of niche medical devices, shot about 68% higher on Jan. 5. Investors were cheering clinical trial results for what could be the company's most important product to date. Is NovoCure a good stock to buy now, or will its recent gains fizzl...
Novocure (NASDAQ: NVCR) stock rallied hard during Thursday's trading session while most growth stocks were selling off. In the video below, I explain why the stock is flying high. I also share a brief background of Novocure and look at a chart to tell you where the stock could be headed nex...
Shares of Chinese biotech company Zai Lab Limited (NASDAQ: ZLAB) were up more than 59.2% for the week as of Thursday afternoon, according to data provided by S&P Global Market Intelligence . The stock closed at $30.70 on Friday and rose to as high as $49.81 on Thursday. Zai La...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: CHIARI VFX / Shutterstock Huadi International (NASDAQ: HUDI ) stock is climbing higher on Thursday even without specific news from the Chinese steel company. What appears to be behind today’s moveme...
News, Short Squeeze, Breakout and More Instantly...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three...
2024-06-13 14:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-04 10:45:03 ET Wells Fargo analyst issues NEUTRAL recommendation for NVCR on June 4, 2024 09:01AM ET. The previous analyst recommendation was Neutral. NVCR was trading at $24.055 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...